U.S. overdose deaths fall again, but experts warn decline may reverse

Drug overdose deaths in the United States fell again in the latest federal count, giving public health officials a rare sign of progress after years of devastation. The Centers for Disease Control and Prevention estimated 70,231 overdose deaths for the 12 months ending in November 2025, a 15.9% decline from the previous year and roughly back to the toll seen before the pandemic surge.

The numbers point to a broad shift. The CDC’s provisional data, which cover all 50 states and the District of Columbia, showed declines across fentanyl, cocaine and methamphetamine, with most states posting lower death totals. Arizona, Colorado and New Mexico were exceptions, with increases that underscore how uneven the crisis remains across the country. The agency also cautioned that provisional counts can understate final totals because some deaths remain under investigation.

Brandon Marshall, a Brown University School of Public Health epidemiologist who serves as scientific director of PreventOverdoseRI and chairs the Rhode Island Opioid Settlement Advisory Committee, said he was “cautiously optimistic” that the decline reflects something deeper than a temporary dip. But he also warned that the trend could turn quickly if the country eases off prevention and treatment efforts. That warning is central to the moment: overdose deaths are falling, but the margin for error is still thin.

Several factors may be pushing deaths down. Public health workers have expanded naloxone access, more people are getting addiction treatment, and opioid settlement dollars are beginning to flow into local responses. Some researchers also point to changes in drug use patterns, including the possibility that fewer teens are starting to use drugs. Others say fentanyl production may have become harder after China said in March 2025 that it had strict controls over fentanyl-related precursor chemicals. U.S. Treasury officials, however, continue to say China-based chemical manufacturers remain a primary source of fentanyl precursors and other illicit opioids entering the United States.

Even with the decline, the crisis is far from over. Deaths remain alarmingly high, and the drug supply keeps changing. CDC overdose-prevention data are designed to help states and local public health partners prioritize resources and tailor response efforts, a reminder that progress depends on sustained investment, not optimism alone. If naloxone access narrows, treatment funding weakens or the street drug market shifts again, the current decline could reverse as quickly as it began.